Significant Ownership of Adimab, LLC

Signature - Title
/s/ Philip Chase - Philip Chase, Chief Executive Officer
Location
Lebanon, NH
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Adimab, LLC.

Follow Filing Activity

Follow Adimab, LLC and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Significant Ownership of Adimab, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
IVVD Invivyd, Inc. Common Stock, $0.0001 par value per share 7.3% $47,210,856 -$448,106 20,262,170 -0.94% Adimab, LLC 23 Dec 2025

Schedules 13D/G Reported by Adimab, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .